REBIRTH Members

Baum, Christopher

Baum, Christopher, Prof. Dr. med.

President Hannover Medical School

Hannover Medical School
Carl-Neuberg-Str. 1
30625 Hannover

Baum.Christopher(at)mh-hannover.de

Education:

1981 - 1982Philosophy, University of Mainz, Germany
1982 - 1989Medicine, Universities of Essen, Freiburg, Hamburg, Germany
1991M.D., University of Hamburg, Germany
1999Post-doctoral lecturing qualification (Habilitation)
2000Right to lecture (Venia legend) in Molecular Medicine, University of Hamburg

Academic appointments and Research posts:

1989 - 1991Resident („Arzt im Praktikum“), Internal Medicine, Research Clinics Borstel
1991 - 1992Postgraduate training in Molecular Biology, University Hamburg
1993 - 1999Research fellow and since 1996 team leader in the Dept. of Cell & Virus Genetics, Heinrich-Pette-Institute of Experimental Virology and Immunology at the University of Hamburg
2000Research Group Leader, Bone Marrow Transplantation, University Hospital Eppendorf, Hamburg
2000 - 2005Associate Professor for Stem Cell Biology, Head of Laboratory for Experimental Cell Therapy, Dept. of Hematology, Hemostaseology and Oncology, Hannover Medical School (MHH)
2003 - 2009Adjunct (APL) Associate Professor, Head of Vector Development, Molecular and Gene Therapy Program, Division of Experimental Hematology am Cincinnati Children’s Hospital in Ohio
2006 - 2013Chair of Institute of Experimental Hematology, MHH
2007 - 2011Academic Integrity Officer (Ombudsman) for Good Scientific Practice, MHH
2007 - 2013Dean of Research, MHH
Since 04/2013President, MHH

Major research interests:

  • Genetic Modification of Hematopoietic Stem Cells and Leukemogenesis
  • Retrovirus Biology and Vector Develompent
  • Regenerative Medicine and Stem Cell Biology
  • Gene and Cell Therapy and Related Toxicology

Selected Publications:

  1. Li Z, Düllmann J, Schiedlmeier B, M. Schmidt M, von Kalle C, Meyer J, Forster M, Stocking C, Ostertag W, Wahlers A, Frank O, Kuehlcke K, Eckert HG, Fehse B, Baum C. Murine leukemia induced by retroviral gene marking. Science 2002; 296:497
  2. Galla M, Will E, Kraunus J, Chen L, Baum C. Retroviral pseudotransduction for targeted cell manipulation. Molecular Cell 2004; 16:309-315
  3. Kustikova O, Fehse B, Modlich U, Düllmann J, Kamino K, von Neuhoff N, Yang M, Schlegelberger B, Li Z*, Baum C*. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 2005; 308: 1171-1174. *co-corresponding
  4. Modlich U, Bohne J, Schmidt M, von Kalle C, Knöß S, Schambach A, Baum C. Cell culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 2006; 108: 2545-2553
  5. Kustikova O, Geiger H, Li Z, Brugman MH, Chambers SM, Shaw CA, Pike-Overzet K, de Ridder D, Staal FJT, Keudell G, Cornils K, Nattamai KJ, Modlich U, Wagemaker G, Goodell MA, Fehse B, Baum C. Retroviral vector insertion sites associated with dominant hematopoietic clones mark “stemness” pathways. Blood 2007; 109:1897-1907
  6. Zychlinski D, Schambach A, Modlich U, Maetzig T, Meyer J, Mishra A, Baum C. Physiological promoters reduce the genotoxic risk of integrating gene vectors. Molecular Therapy 2008; 18:718-725
  7. Voelkel C, Galla M, Maetzig M, Warlich E, Kuehle J, Zychlinski D, Bode J, Cantz T, Schambach A*, Baum C*. Protein transduction from retroviral Gag precursors. Proceedings of the National Academy of Sciences USA 2010; 107:7805-7810 *co-corresponding
  8. Suerth JD, Maetzig T, Galla M, Baum C, Schambach A. Self-inactivating alpharetroviral vectors with a split-packaging design. Journal of Virology 2010; 84:6626-35
  9. Hacein-Bey-Abina S, Pai SY, Gaspar HB, Armant M, Berry CC, Blanche S, Bleesing J, Blondeau J, de Boer H, Buckland KF, Caccavelli L, Cros G, De Oliveira S, Fernández KS, Guo D, Harris CE, Hopkins G, Lehmann LE, Lim A, London WB, van der Loo JC, Malani N, Male F, Malik P, Marinovic MA, McNicol AM, Moshous D, Neven B, Oleastro M, Picard C, Ritz J, Rivat C, Schambach A, Shaw KL, Sherman EA, Silberstein LE, Six E, Touzot F, Tsytsykova A, Xu-Bayford J, Baum C, Bushman FD, Fischer A, Kohn DB, Filipovich AH, Notarangelo LD, Cavazzana M, Williams DA, Thrasher AJ. A modified y-retrovirus for X-linked severe combined immunodeficiency. New England Journal of Medicine 2014 Oct 9;371(15):1407-17.
  10. Schwarzer A, Holtmann H, Brugman M, Meyer J, Schauerte C, Zuber J, Steinemann D, Schlegelberger B, Li Z, Baum C. Hyperactivation of mTORC1 and mTORC2 by multiple oncogenic events causes addiction to eIF4E-dependent mRNA translation in T-cell leukemia. Oncogene. 2015 Jul;34(27):3593-604


[back to listing]
test
This website uses cookies and the web analytics service Google Analytics. Click here for further information on privacy.
I agree